Aratana Therapeutics, a US-based biopharmaceutical company developing medicines for cats and dogs, has raised $12m in its series C round.
Investors included RaQualia Pharma, which provides clinical and pre-clinical candidates for human patients, state-backed Kansas Bioscience Authority and venture capital (VC) firms Cultivian Ventures, Avalon Ventures and MPM Capital.
In December 2011, Aratana raised $15m in its B round from its VC firms and family office Ewing Marion Kauffman Foundation, and $20m in an A round at the start of that year.